Comparative safety of high-efficacy disease-modifying therapies in relapsing –remitting multiple sclerosis: a systematic review and network meta-analysis

ConclusionThe commonly reported AEs are generally similar among high-efficacy DMTs. However, based onP scores for most analyzed endpoints, natalizumab and ocrelizumab were shown to be the safest DMTs. Considering the limitations of indirect comparisons, further research is needed to confirm our findings, preferably head-to-head RCTs and large observational studies.
Source: Neurological Sciences - Category: Neurology Source Type: research